CD19 and bacterial infectious disease: A large retrospective analysis of patients with DLBCL receiving CD19 CAR T-cells identified a significant reduction of severe bacterial infections with fluoroquinolone prophylaxis in patients who were categorized as CAR-HEMATOTOXhigh but not in those who were CAR-HEMATOTOXlow at baseline (41).